share_log

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

Canaccord Genuity维持对Rhythm Pharmicals的买入,将目标股价下调
Benzinga ·  05/08 12:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.

Canaccord Genuity分析师惠特尼·伊杰姆维持Rhythm Pharmicals(纳斯达克股票代码:RYTM)的买入并将目标股价从80美元下调至79美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发